Clinical Trials on Meningitis, Pneumococcal in Germany

Total 37 results

Pfizer

Completed

Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)

Neisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)

Germany
Pfizer

Completed

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Meningitis | Meningococcal Vaccine | rLP2086 | Repevax | N Meningitidis Serogroup B

Germany, Finland, Poland
Charite University, Berlin, Germany

Recruiting

Early Diagnosis of Native and Device-associated Meningitis

Bacterial Meningitis | Implant Infection | Fungal Meningitis

Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Prevenar in High-Risk Children

Pneumococcal Disease

Germany
LimmaTech Biologics AG

Completed

Phase I to Test a New Pneumococcal Vaccine

Pneumonia, Bacterial | Pneumococcal Pneumonia

Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Vaccines, Pneumococcal

Germany
Mundipharma Research Limited

Completed

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

Brain Metastases | Solid Tumour Neoplastic Meningitis

Austria, Germany
Novartis Vaccines

Completed

Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers

Meningococcal Meningitis

Germany
Novartis Vaccines
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Hepatitis B | Hepatitis A | Meningococcal Disease | Meningococcal Meningitis

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland, Germany, Hungary, Spain
GlaxoSmithKline

Completed

A Sourcing Study to Collect Human Blood Samples From Healthy Adults

Meningitis, Meningococcal

Australia, Germany
Pfizer

Completed

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, Pneumococcal Conjugate Vaccine

United States, Spain, France, Canada, Germany, Czechia, Sweden, Belgium, Poland, Netherlands
Jena University Hospital

Completed

Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels

Pneumococcal Infections

Germany
Valneva Austria GmbH
PATH

Completed

Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47

Pneumococcal Infections

Germany
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
GlaxoSmithKline

Active, not recruiting

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Meningitis, Meningococcal

Germany, United States
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

Pneumococcal Disease

Argentina, Australia, Colombia, Germany, Israel, Korea, Republic of, New Zealand, Spain, Taiwan, Turkey, United Kingdom
Novartis
Novartis Vaccines

Completed

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Japanese Encephalitis | Rabies | Yellow Fever | Meningococcal Disease | Typhoid | Meningococcal Meningitis

Czech Republic, Germany
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

Pneumococcal Infection

United States, Australia, Belgium, Chile, Germany, Korea, Republic of, New Zealand, Puerto Rico, Sweden, Taiwan, Turkey
Pfizer

Completed

Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants

Meningitis, Meningococcal

Austria, Germany
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Pneumococcal Disease

Spain, United States, Canada, Chile, Greece, Germany, Finland, Argentina, Czechia, Hungary, Puerto Rico
GlaxoSmithKline

Completed

Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™

Streptococcus Pneumoniae | Infections, Streptococcal

Germany
GlaxoSmithKline

Completed

Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Streptococcus Pneumoniae Vaccines | Infections, Streptococcal

Germany
University of Rostock

Completed

Neurocognitive Impairment in Pediatric Patients With Meningoencephalitis and Sepsis-associated Encephalopathy (NCIPED)

Central Nervous System Diseases | Delirium | Brain Injuries | Critical Illness | Encephalopathy | Inflammatory Disease

Germany
Hannover Medical School
Charite University, Berlin, Germany; University of Leipzig

Unknown

Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ) (PROVID-CAPNETZ)

COVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious Organisms

Germany
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (PNEU-PED-EU-1)

Pneumococcal Infections

Australia, Belgium, Czechia, Estonia, Germany, Greece, Poland, Russian Federation, Spain
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Pneumococcal Infections

United States, Australia, Canada, Finland, Germany, Israel, Malaysia, Peru, Taiwan, Thailand
Pfizer

Completed

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

Pneumococcal Infections

Sweden, United States, Germany
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Pneumococcal Infections

United States, Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Mexico, Sweden
GlaxoSmithKline

Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain, Germany, Poland
Pfizer

Completed

Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216

Meningococcal Meninigitis, Serogroup C

Austria, Germany
Infectopharm Arzneimittel GmbH
INPADS GmbH; Dr. Oestreich + Partner GmbH

Recruiting

Fosfomycin i.v. for Treatment of Severely Infected Patients (FORTRESS)

Respiratory Tract Infections | Sepsis | Encephalitis | Bacterial Infections | Intraabdominal Infections | Bacteremia | Skin Diseases, Bacterial | Pneumonia, Bacterial | Urinary Tract Infections | Meningitis, Bacterial | Central Nervous System Bacterial Infections | Soft Tissue Infections | Endocarditis, Bacterial | Bone Diseases, Infectious and other conditions

Germany, Austria, Greece, Italy, United Kingdom
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
GlaxoSmithKline

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Streptococcus Pneumoniae Vaccines

Spain, Germany, Poland
GlaxoSmithKline

Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Germany, France, Canada

Clinical Trials on Meningitis, Pneumococcal in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations